Extensively Drug-resistant Tuberculosis, Italy and Germany

Risk Factors for Poor Treatment Outcomes in Patients With MDR-TB and XDR-TB in China: Retrospective Multicenter Investigation

“…We also found that in contrast to the poor treatment outcome, the mortality rate of XDR-TB was 4.7 %, much lower than those reported by a few other studies [7,11,33]. Most patients can live long, but had protracted infectious period, similar to other publications of HIV-seronegative cohorts with XDR-TB [11,31,34]. In China, the treatment success rate of MDR-and XDR-TB is low.…”

Treatment of Drug-Resistant Tuberculosis: Review

“…YİD-TB ile ölüm riski arasında belirgin bir ilişki söz konusudur. 37 Aynı şekilde, özellikle HIV ile enfekte YİD-TB hastalarının mortalite oranları hayli yüksektir. 41 HIV enfeksiyonu bulunan ve bulunma-yanlar arasında izlenen ölüm sayısında, diğer çoğu çalışmadan farklı olarak anlamlı farklılık saptanmamıştır [HIV enfeksiyonu olan 82 hastanın 34 (%41)'ü ve HIV enfeksiyonu bulunmayan 92 hastanın 28 (%30)'i kaybedilmiştir].…”

Synthesis and Antitubercular Activity of Piperidine and Morpholine 1, 8 Naphthyridine Analogues

“…Growth of Mycobacterium tuberculosis H37Rv led to consumption of the substrate and release of [14]CO2 into the atmosphere above the medium in the sealed vial, and the BACTEC 460 TB (Johnston Laboratories, Towson, Md) was used to detect the amounts of [14]CO2 and recorded it as growth index (GI) [17]. Appropriate solutions of the studied compounds were added in a volume of 0.1 ml to vials containing 7H12 broth medium, to achieve the desired final concentrations.…”

“…The 7H12 broth medium which contained [14]C-labeled substrate (palmitic acid) as a single source of carbon, was used in these studies. Growth of Mycobacterium tuberculosis H37Rv led to consumption of the substrate and release of [14]CO2 into the atmosphere above the medium in the sealed vial, and the BACTEC 460 TB (Johnston Laboratories, Towson, Md) was used to detect the amounts of [14]CO2 and recorded it as growth index (GI) [17].…”

“…Tuberculosis control requires new drugs that act at novel drug targets to help combat resistant forms of M. tuberculosis and reduce treatment duration [12][13][14].…”